Malaysia Biotech Head Calls For More Private Involvement
This article was originally published in PharmAsia News
The head of Malaysia's biotechnology agency, BiotechCorp, called for more involvement by the private sector if the nation is to meet its goal of doubling the number of biotech firms by the end of this year. Of 63 Malaysian biotechs, 25 are in the health care business. BiotechCorp CEO Datuk Iskandar Mizal Mahmood said government funding needs to be complemented by private financing and capital markets if the goal of 120 biotech firms in Malaysia by the end of the year is to be met. After that, the government's master plan aims for a commercialization phase between 2011 and 2015. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.